S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%

Investing

Medivation Jumps on Prostate Cancer Drug Test (MDVN, DNDN, JNJ)

Photo of Paul Ausick
By Paul Ausick Updated Published

Shares of development-stage drug maker Medivation Inc. have risen sharply today as the company said that its MDV3100 late-stage prostate cancer drug for patients who have failed chemotherapy extends life expectancy by 4.8 months. The drug does not challenge Dendreon Inc.’s (NASDAQ: DNDN) Provenge prostate cancer treatment, which attacks early-stage prostate cancer, but will compete with Johnson & Johnson’s (NYSE: JNJ) Zytiga late-stage drug.

Medivation’s shares are up nearly 24% at $68.59 after posting a new 52-week high of $68.81 earlier. See today’s story on Dendreon and Provenge here.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income
Michael Williams |

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income
The Real Cost of Retiring in The Villages, Florida, on $2,000 a Month
Michael Williams |

The Real Cost of Retiring in The Villages, Florida, on $2,000 a Month

Continue Reading

Jon C. Ogg |

Total Curve Ball for Prostate Cancer Field (DNDN, JNJ, MDVN)

Dendreon Corporation (NASDAQ: DNDN) may be losing its favor as the prostate cancer drug of choice.  That is at least…

David J. Phillips |

Dendreon Buyout, How Imminent?

Though near-term growth visibility for its cancer vaccine Provenge remains cloudy, Seattle-based Dendreon (DNDN) could be an attractive takeover candidate…

Douglas A. McIntyre |

Comment From The Stock Masters

All eyes are on Dendreon Corporation (DNDN) today and their shares have been halted ahead of their meeting with the…

Jon C. Ogg |

Dendreon In Trouble

AuthorDendreon Corporation (NASDAQ: DNDN) is in trouble.  That is what the performance is telling investors.  The maker of Provenge as…

Jon C. Ogg |

Dendreon Gets Prostate Cancer Competition for Provenge from Bayer’s Xofigo

via Wikimedia CommonsDendreon Corp. (NASDAQ: DNDN) has been facing problems getting its Provenge sales for advanced metastatic prostate cancer through…

Douglas A. McIntyre |

A Make or Break Week for Dendreon (DNDN)

Dendreon(DNDN-NASDAQ) is going to be one of "THE TOP ISSUES" this week.  The company will have and FDA review panel…

Douglas A. McIntyre |

Dendreon Sets Stage for 2008 for PROVENGE

Dendreon (NASDAQ:DNDN) has issued a press release noting that it has completed its target enrollment of 500 patients in phase…

cgblaine22 |

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug,…

Jon C. Ogg |

Dendreon Shows Poor Provenge Sales, Implosion Risk Rising

ThinkstockDendreon Corp. (NASDAQ: DNDN) just cannot catch a break. Despite having what was supposed to be one of the best…

Top Gaining Stocks

Airbnb
ABNB • Vol: 15,913,532
Microchip Technology
MCHP • Vol: 19,139,274
Palantir
PLTR • Vol: 77,244,625
Moderna
MRNA • Vol: 6,820,582
Axon Enterprise
AXON • Vol: 1,591,869

Top Losing Stocks

Trade Desk
TTD • Vol: 133,458,224
Coterra Energy
CTRA • Vol: 73,319,495
Akamai
AKAM • Vol: 8,143,961
Zoetis
ZTS • Vol: 12,784,553
ResMed
RMD • Vol: 3,810,438